Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 4/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 7/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18822678 | 0.98 | DRD4 (0.41) | DRD4DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL9594487 | 0.96 | DRD4 (0.46) | DRD4DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL20544402 | 0.75 | MEN1 (0.39) | SLC2A1 | |
| SCHEMBL26703722 | 0.75 | PNMT (0.37) | PARP1SLC2A1 | |
| SCHEMBL16416075 | 0.71 | SLC2A1 (0.36) | DRD4DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL14603877 | 0.69 | NOTUM (0.35) | DRD4HTR2AHTR2CHTR2BMAPK10 | |
| SCHEMBL10509 | 0.69 | — | — | |
| SCHEMBL30994991 | 0.68 | TRIM24 (0.39) | DRD4DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL18687432 | 0.68 | ALDH1A1 (0.41) | PARP1POLBGAAALDH1A1 | |
| SCHEMBL20836293 | 0.68 | PTPN1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257049-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | PRAGMA THERAPEUTICS (FR) | 2025-08-14 | — | — | US | claimed |
| US-12234218-B2 | Heterocyclic compounds as modulators of mGluR7 | PRAGMA THERAPEUTICS (FR) | 2025-02-25 | — | — | US | claimed |
| US-20220363664-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | PRAGMA THERAPEUTICS (FR) | 2022-11-17 | — | — | US | claimed |
| US-11414395-B2 | Heterocyclic compounds as modulators of mGluR7 | PRAGMA THERAPEUTICS (FR) | 2022-08-16 | — | — | US | claimed |
| US-20250257049-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | PRAGMA THERAPEUTICS (FR) | 2025-08-14 | — | — | US | disclosed |
| US-12234218-B2 | Heterocyclic compounds as modulators of mGluR7 | PRAGMA THERAPEUTICS (FR) | 2025-02-25 | — | — | US | disclosed |
| CN-118139858-A | Pyrazin-3 (2H) -one derivatives | 吉利德科学公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-116406356-A | Process for the preparation of 6- (4-nitro-phenoxy) -2H-pyridazin-3-one and 6- (4-amino-phenoxy) -2H-pyridazin-3-one derivatives as intermediates for thyroid hormone analogues | 马德里加尔制药公司 | 2023-07-07 | — | — | CN | disclosed |
| US-20230144411-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | DART NEUROSCIENCE LLC | 2023-05-11 | — | — | US | disclosed |
| US-20220363664-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | PRAGMA THERAPEUTICS (FR) | 2022-11-17 | — | — | US | disclosed |
| US-11414395-B2 | Heterocyclic compounds as modulators of mGluR7 | PRAGMA THERAPEUTICS (FR) | 2022-08-16 | — | — | US | disclosed |
| US-8258134-B2 | Pyridazinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | disclosed |
| EP-2120579-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| WO-2009127544-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-22 | — | — | WO | disclosed |
| EP-1953147-A1 | HETEROCYCLIC COMPOUND AND MEDICINAL APPLICATION THEREOF | Japan Tobacco, Inc. (JP) | 2008-08-06 | — | — | EP | disclosed |
| WO-2008083027-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | WO | disclosed |
| EP-1058681-A1 | NOVEL ALLYLTHIOPYRIDAZINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | Seoul Pharm. Co., Ltd. (KR) | 2000-12-13 | — | — | EP | disclosed |
| WO-1999036407-A1 | NOVEL ALLYLTHIOPYRIDAZINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | SEOUL PHARM. CO., LTD. (KR) | 1999-07-22 | — | — | WO | disclosed |
| US-3883531-A | Perhydrophthalazin-1(2H)-one and process | LEPETIT SPA | 1975-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257049-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | GRM7, GRM1, GRM2 | DRD4 525/4885DRD2 269/4885HTR2A 239/4885 |
| US-12234218-B2 | Heterocyclic compounds as modulators of mGluR7 | GRM7, GRM1, GRM2 | DRD4 525/4885DRD2 269/4885HTR2A 239/4885 |
| US-20220363664-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | GRM7, GRM1, GRM2 | DRD4 525/4885DRD2 269/4885HTR2A 239/4885 |
| US-20230144411-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | OPRL1, OPRK1, NOP56 | DRD4 271/4885DRD2 176/4885HTR2A 66/4885 |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | GCK, GCKR, PDXK | DRD4 3506/4885DRD2 3311/4885HTR2A 1880/4885 |
| US-11414395-B2 | Heterocyclic compounds as modulators of mGluR7 | GRM7, GRM1, GRM3 | DRD4 529/4885DRD2 260/4885HTR2A 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.